ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
01 avr. 2024 16h05 HE
|
ReShape Lifesciences Inc
Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference...
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
28 mars 2024 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the...
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
04 mars 2024 08h31 HE
|
ReShape Lifesciences Inc
2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Partner Continues IRVINE,...
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
22 févr. 2024 08h31 HE
|
ReShape Lifesciences Inc
FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape...
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
24 janv. 2024 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that bariatric...
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
20 déc. 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it has...
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
12 déc. 2023 16h05 HE
|
ReShape Lifesciences Inc
FLEX Technology Designed to Improve the Patient Experience Company Initiating U.S. Product Launch IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the...
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
21 nov. 2023 08h06 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has...
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
08 nov. 2023 16h05 HE
|
ReShape Lifesciences Inc
Third Quarter Core Operating Expenses Reduced 37% Compared to Third Quarter of 2022 Cost Reduction Plan To Reduce Operating Expenses In 2024 by Over 40% Compared to 2023 Conference Call to be Held...
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
06 nov. 2023 08h31 HE
|
ReShape Lifesciences Inc
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will...